(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
02 January 2020 (02.01.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/001657 A1

(51) International Patent Classification:
C12N 15/09 (2006.01) *A61K 48/00* (2006.01)
C12N 15/63 (2006.01) *A61P 27/02* (2006.01)
C12N 15/86 (2006.01)

(21) International Application Number:
PCT/CN2019/094136

(22) International Filing Date:
01 July 2019 (01.07.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
201810703168.7 29 June 2018 (29.06.2018) CN
201810702492.7 29 June 2018 (29.06.2018) CN
PCT/CN2018/095023
09 July 2018 (09.07.2018) CN
201810948193.1 20 August 2018 (20.08.2018) CN
PCT/CN2018/103937
04 September 2018 (04.09.2018) CN
201811221305.X 19 October 2018 (19.10.2018) CN
201811230856.2 22 October 2018 (22.10.2018) CN
PCT/CN2018/113799
02 November 2018 (02.11.2018) CN
PCT/CN2018/118662
30 November 2018 (30.11.2018) CN
PCT/CN2019/070461
04 January 2019 (04.01.2019) CN

(71) Applicant: **WUHAN NEUROPHTH BIOLOGICAL TECHNOLOGY LIMITED COMPANY** [CN/CN]; C270-271 B1, No. 666 Ave Gaoxin, Wuhan, Hubei 430060 (CN).

(72) Inventor: **LI, Bin**; C270-271 B1, No. 666 Ave Gaoxin, Wuhan, Hubei 430060 (CN).

(74) Agent: **METIS IP (CHENGDU) LLC**; Room 808, 8th Floor, Building B7, Block D, Tianfu Jingrong Center, No. 99 West Section of Hupan Road, Tianfu New District, Chengdu, Sichuan 610213 (CN).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) Title: COMPOSITIONS AND METHODS FOR TREATING LEBER'S HEREDITARY OPTIC NEUROPATHY




FIG. 5

(57) Abstract: Disclosed herein is a recombinant nucleic acid, comprising: a mitochondrial targeting sequence; a mitochondrial protein coding sequence, wherein said mitochondrial protein coding sequence encodes a polypeptide comprising a mitochondrial protein; and a 3'UTR nucleic acid sequence. Also disclosed is a pharmaceutical composition comprising the recombinant nucleic acid and a method of treating Leber's hereditary optic neuropathy (LHON) using the pharmaceutical composition.

WO 2020/001657 A1

[Continued on next page]

Published:
— *with international search report (Art. 21(3))*
— *with sequence listing part of description (Rule 5.2(a))*